Washington, D.C. – 31.05.2026: A new drug called Daraxonrasib has shown promising results in clinical trials for the treatment of metastatic pancreatic cancer. The experimental drug targets a mutation in the KRAS protein, which is present in over 90 percent of all pancreatic carcinomas and has so far been difficult to treat. In a randomized study with 500 patients, Daraxonrasib increased median survival time to 13.2 months compared to 6.7 months with standard chemotherapy – nearly a doubling.
Side effects were lower compared to conventional treatment, and patients’ quality of life improved significantly. These significant results were presented at the annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago and were also published in the prestigious “New England Journal of Medicine.” The US Food and Drug Administration (FDA) is currently fast-tracking approval of the drug and has already enabled limited use through an expanded access program.
Daraxonrasib was developed by Revolution Medicines and relies on an innovative molecular “glue” principle to specifically block the KRAS mutation, which has so far been considered a major breakthrough. Experts see this drug as a milestone that could herald a paradigm shift in the therapy of pancreatic cancer.
In France, a national prevention approach called the “Interception” program is starting simultaneously, focusing on high-risk patients and promoting early diagnoses. This includes regular screenings and biannual check-ups but has so far only covered about ten percent of potential cases. Expanding such programs to include additional risk factors such as smoking, obesity, and environmental exposures is considered an important goal. Research on biological markers for early detection is also being vigorously advanced.
The availability of Daraxonrasib in France is expected in 2027, which should significantly expand the therapeutic options. However, the challenge of resistance development against the drug remains. For this reason, research on combination therapies and further targeted inhibitors is ongoing to improve the effectiveness and durability of treatment.
Overall, the progress with Daraxonrasib represents a significant step in the treatment of a previously extremely aggressive and difficult-to-cure cancer. The combination of innovative therapy and targeted prevention programs could increase survival rates in the long term and significantly improve the quality of life for affected patients. Scientists and the medical community worldwide are closely following further developments with great interest.
New treatment options like Daraxonrasib offer hope of longer life for patients with metastatic pancreatic cancer and may sustainably change clinical practice in the coming years. Continuous research and clinical testing remain crucial to achieving substantial progress in a therapy landscape that has so far been unsatisfactory.
Sources
- AP News
- Le Monde